|
|
|
Insider
Information: |
Bienaime Jean Jacques |
Relationship: |
|
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
8 |
|
Direct
Shares |
540,054 |
|
Indirect Shares
|
247,533 |
|
|
Direct
Value |
$43,092,104 |
|
|
Indirect Value
|
$21,938,850 |
|
|
Total
Shares |
787,587 |
|
|
Total
Value |
$65,030,954 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
1
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
1
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
-13.1%
|
-5.5%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Biomarin Pharmaceutical Inc |
BMRN |
Director |
2024-05-20 |
473,792 |
2024-05-20 |
247,533 |
Premium* |
|
Neurogesx Inc |
NGSX |
Director |
2011-07-26 |
21,748 |
|
0 |
Premium* |
|
InterMune Inc |
ITMN |
Director |
2014-09-29 |
0 |
2012-04-06 |
0 |
Premium* |
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2014-05-16 |
706 |
2013-05-28 |
0 |
Premium* |
|
Immunic Inc |
IMUX |
Director |
2018-09-24 |
18,500 |
2001-04-23 |
0 |
Premium* |
|
Incyte Corp |
INCY |
Director |
2023-06-14 |
15,493 |
|
0 |
Premium* |
|
Immunome Inc. |
IMNM |
|
2024-05-21 |
9,615 |
|
0 |
Premium* |
|
Keros Therapeutics, Inc. |
KROS |
|
2024-06-01 |
200 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
853 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 30 of 35
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2016-03-03 |
4 |
D |
$89.57 |
$805,145 |
D/D |
(8,989) |
331,511 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2020-01-08 |
4 |
OE |
$21.51 |
$86,040 |
D/D |
4,000 |
331,530 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-03-13 |
4 |
OE |
$14.39 |
$43,170 |
D/D |
3,000 |
331,701 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-10-25 |
4 |
OE |
$21.51 |
$107,550 |
D/D |
5,000 |
332,520 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-12-27 |
4 |
OE |
$21.51 |
$107,550 |
D/D |
5,000 |
332,530 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-03-07 |
4 |
OE |
$14.39 |
$57,560 |
D/D |
4,000 |
332,701 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-03-12 |
4 |
OE |
$14.39 |
$57,560 |
D/D |
4,000 |
332,701 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
45,320 |
333,610 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-03-11 |
4 |
OE |
$14.39 |
$71,950 |
D/D |
5,000 |
333,701 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2016-10-14 |
4 |
OE |
$17.86 |
$196,460 |
D/D |
11,000 |
334,368 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-03-16 |
4 |
D |
$80.72 |
$448,803 |
D/D |
(5,560) |
334,983 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-04-14 |
4 |
AS |
$83.66 |
$836,600 |
D/D |
(10,000) |
334,983 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-04-18 |
4 |
AS |
$81.91 |
$1,638,200 |
D/D |
(20,000) |
334,983 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-04-28 |
4 |
AS |
$83.79 |
$1,675,800 |
D/D |
(20,000) |
334,983 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-04-29 |
4 |
AS |
$81.95 |
$409,750 |
D/D |
(5,000) |
334,983 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-04-29 |
4 |
A |
$62.41 |
$21,281 |
D/D |
341 |
335,324 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-05-05 |
4 |
AS |
$84.14 |
$841,400 |
D/D |
(10,000) |
335,324 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-05-06 |
4 |
AS |
$81.00 |
$1,620,000 |
D/D |
(20,000) |
335,324 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2023-02-10 |
4 |
OE |
$67.81 |
$1,017,150 |
D/D |
15,000 |
335,324 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-03-15 |
4 |
AS |
$94.40 |
$377,600 |
D/D |
(4,000) |
335,338 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
34,780 |
335,338 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2020-01-14 |
4 |
OE |
$21.51 |
$172,080 |
D/D |
8,000 |
335,530 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-03-19 |
4 |
OE |
$14.39 |
$14,390 |
D/D |
1,000 |
336,338 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2019-05-10 |
4 |
OE |
$14.39 |
$143,900 |
D/D |
10,000 |
336,520 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2021-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
41,350 |
337,002 |
0 |
- |
|
853 Records found
|
|
Page 30 of 35 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|